Dr. Pincus has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Centocor, Inc., and UCB, Inc., and has received research grants from Bristol-Myers Squibb, Inc., and UCB, Inc.
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): Agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds
Version of Record online: 28 JAN 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 2, pages 181–189, February 2010
How to Cite
Pincus, T., Swearingen, C. J., Bergman, M. J., Colglazier, C. L., Kaell, A. T., Kunath, A. M., Siegel, E. L. and Yazici, Y. (2010), RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): Agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res, 62: 181–189. doi: 10.1002/acr.20066
- Issue online: 28 JAN 2010
- Version of Record online: 28 JAN 2010
- Manuscript Accepted: 23 SEP 2009
- Manuscript Received: 7 APR 2009
- Arthritis Foundation
- Bristol-Myers Squibb
- Jack C. Massey Foundation
- 1Introduction OMERACT 5: International Consensus Conference on Outcome Measures in Rheumatology. J Rheumatol 2001; 28: 395–7., , , , .
- 3OMERACT Committee. Proceedings of the OMERACT conferences on outcome measures in rheumatoid arthritis clinical trials: 29 April – 3 May 1992; Maastricht, The Netherlands. J Rheumatol 1993; 20: 527–91., , and the
- 12FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36–41., , , , , , et al, for the
- 17Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815–22., , , , , , et al.
- 23An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008; 47: 345–9., , , , , .
- 26An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625–30., , , , , , et al.
- 27Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005; 52: 1031–6., , .
- 30Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220–30., , .
- 42High/moderate versus low activity/remission patient proportions are similar according to DAS28 (Disease Activity Score), CDAI (Clinical Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data) in ATTRACT and ASPIRE Infliximab (INFX) clinical trials in patients with rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 433., , .
- 45Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008; 66: 216–23..
- 46The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52: 3873–9., , , , .